Gustave Roussy Institute. Paris, France

The host of this seminar is Marcus Buscbeck.

Thomas Mercher earned a PhD from Pierre & Marie Curie University (Paris, France) and completed a post-doctoral fellowship at Harvard Medical School & Brigham and Women’s Hospital (Boston, USA). He is the director of the INSERM unit "Oncogenesis, resistance and therapeutic targets of pediatric cancers" and leads the team "Biology of pediatric blood cancers" at the Gustave Roussy cancer center. His work focuses on the genetic, epigenetic and functional characterization of aggressive pediatric acute myeloid leukemia (AML) associated with fusion oncogenes. He contributed to the understanding of the role of ontogeny in the development of pediatric-specific AML using inducible transgenic models. His team also develops human cell-based leukemogenesis and patient-derived models of acute myeloid leukemia to perform preclinical testing of novel therapeutic strategies, with recent work involving primary human fetal hematopoietic cells and induced pluripotent stem cells. He obtained several National Cancer Institute grants and coordinated the french national multidisciplinary PEDIAC research program on the origins of pediatric cancers.

This activity is supported in part through the IJC's AECC Scientific Foundation Center Accreditation 2024-2028.

IJC Auditorium + Online
Registration here